Published

09 Dec 25

Updated

26 Jun 26

Views

129

Not Invested

Pharming GroupPHARM

Fair Value

€2.36

Share price26 Jun

€0.9958.1% undervalued

1Y-20.11%

7D0.061%

Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

09 Dec 25

Updated

26 Jun 26

Views

129

Not Invested

Shared on 26 Jun 26

Fair value Increased 12%

PHARM: Expanded Rare Disease Approvals Will Drive Future Upside Potential

Pharming gets a fresh boost as regulators move closer to letting more children use its rare-disease medicine, while Europe also opens the door to a new launch. The catch: the updated outlook leans heavily on the company hitting its growth and profit goals, and the market’s expectations could be less forgiving if it doesn’t.

19 views

Fair Value vs Share Price

€2.36

vs €0.9958.1% undervalued

6.2%

Revenue growth

7.4%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Pharming Group

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with reasonable growth potential.

Market cap€698.9m

PB3.0x

Estimated Growth13.3%

Dividend YieldN/A

Full analysis

CEO & management

Fabrice Chouraqui

CEO

2.9yrs

CEO Tenure

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.